Erythropoietin for treatment of multi-organ failure

Details Erythropoietin for treatment of multi-organ failure Erythropoietin for treatment of multi-organ failure

2005-11-22

2011-11-29

Kemmerer, Elizabeth C (Department: 1647)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

C530S399000

Reexamination Certificate

active

08067365

ABSTRACT:
The compositions and methods disclosed herein are for prevention or treatment of multi-organ failure with erythropoietin. The usefulness of the present invention is that erythropoietin may act to prevent the onset of MOF in a patient at risk of developing it. The present invention may further lessen the effect in one or more affected organs in a patient at risk of developing MOF or in one already diagnosed with it.

REFERENCES:
patent: 6531121 (2002-07-01), Brines et al.
patent: 6784154 (2003-05-01), Westenfelder
patent: 2002/0065214 (2002-05-01), Iaina et al.
patent: 2003/0104988 (2003-06-01), Brines et al.
patent: 2005/0075287 (2005-04-01), Van Gilst
Wells, J.A. Additivity of Mutational Effects in Proteins. Biochemistry 29:8509-8517 (1990).
Ngo et al. Computational Complexity, Protein Structure Prediction and the Levinthal Paradox. The Protein Folding Problem and Tertiary Structure Prediction, pp. 433-440 and 492-495 (1994).
Bahlmann et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoietin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation vol. 110:1006-1012 (published on line Aug. 9, 2004).
Coleman et al. Science review: Recombinant human erythropoietin in critical illness: a role beyond anemia? Critical Care 8:337-341 (available online Jun. 16, 2004).
Parke et al. Multiple organ dysfunction syndrome. Inflammopharmacology, vol. 11, No. 1, pp. 87-95 (2003).
Gabriel et al. High-dose recombinant human erythropoietin stimulates reticulocyte production in patients with multiple organ dysfunction syndrome. Journal of Trauma 44(2):361-7 (Feb. 1998).

Affiliated with

Also associated with

Rating

Erythropoietin for treatment of multi-organ failure does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Erythropoietin for treatment of multi-organ failure, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Erythropoietin for treatment of multi-organ failure will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4308520